Drug Launch Timing and International Reference Pricing.

Area of Science:

• Health Economics
• Pharmaceutical Policy
• Market Entry Strategy

Background:

• International reference pricing (IRP) influences pharmaceutical pricing strategies.
• Understanding drug launch timing is crucial for market access and revenue.
• Existing models often simplify the complexities of global pricing negotiations.

Purpose of the Study:

• To analyze pharmaceutical firms' drug launch timing decisions under international reference pricing.
• To investigate the impact of different reference pricing mechanisms on market entry.
• To determine how firms strategize launch sequencing across countries with varying price referencing.

Main Methods:

• Game-theoretic modeling of pharmaceutical firm pricing and launch decisions.
• Analysis of a dynamic model with international price referencing.
• Comparative statics to assess the impact of reference set size and composition.

Main Results:

• No drug withdrawal observed across countries or time periods under full price referencing.
• Drug sales in a country imply sales in all countries with higher willingness to pay.
• No inherent incentive for firms to delay drug launches.
• Profitability increases as the set of reference countries shrinks.

Conclusions:

• IRP systems, particularly those with transitive referencing, create predictable launch patterns.
• Firms do not face strong incentives to delay launches, ensuring market availability.
• Reducing the scope of reference pricing can enhance pharmaceutical firm profits.